GURU.Markets stock price, segment price, and overall market index valuation
The company's share price HCM
HUTCHMED is a biopharmaceutical company focused on developing drugs for the treatment of cancer and immune diseases. Its share price is dependent on the success of clinical trials and the commercialization of its products both in China and globally.
Share prices of companies in the market segment - General oncology therapy
HUTCHMED is a biopharmaceutical company focused on developing cancer treatments. We classify it as a general oncotherapeutics company, and the chart below reflects the overall trends and investor sentiment in this biotech sector.
Broad Market Index - GURU.Markets
HUTCHMED is an innovative biopharmaceutical company that develops and commercializes targeted drugs and immunotherapies for the treatment of cancer. As a component of the GURU.Markets index, it represents the Chinese biotech sector. The chart below shows the US market. See how HCM shares compare to the US market.
Change in the price of a company, segment, and market as a whole per day
HCM - Daily change in the company's share price HCM
For HUTCHMED, an oncology company, change_co is a measure of the sector's inherently high volatility. Each daily change reflects sensitivity to news about clinical trials and regulatory decisions in China and the US. This metric isn't just noise, but a critical component of the models on System.GURU.Markets that assess biotech risk.
Daily change in the price of a set of shares in a market segment - General oncology therapy
HUTCHMED (China) Limited is an oncology company. This chart illustrates the extreme volatility of the biotech sector. Comparison with HCM's performance, which focuses on the Chinese market, helps understand its unique regulatory and commercial risks.
Daily change in the price of a broad market stock, index - GURU.Markets
HUTCHMED is a biopharmaceutical company specializing in the development of drugs to treat cancer and immune diseases. Oncology is a highly volatile sector. The chart below reflects average fluctuations in this industry, providing context for evaluating HUTCHMED shares.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization HCM
HUTCHMED is a global biotech company developing drugs to treat oncology. Its shares react to news about clinical programs in various countries. This complex, multi-factor dynamic contributes to the overall volatility.
Annual dynamics of market capitalization of the market segment - General oncology therapy
HUTCHMED (China) Limited is a biopharmaceutical company focused on the development and commercialization of targeted therapies and immunotherapies for cancer treatment. This chart shows how its scientific advancements, partnerships, and access to the vast Chinese market impact its performance relative to the global biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
HUTCHMED is a Chinese biotech company whose stock price (ADR) is driven by two factors: the success of its R&D platform and investor sentiment toward the Chinese market. The chart is a complex story, where scientific potential contends with geopolitical and regulatory risks, creating high volatility.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization HCM
HUTCHMED, a biopharmaceutical company focused on the development and commercialization of oncology drugs in China and globally, features monthly fluctuations reflecting clinical trial news and the commercial success of its drugs in the vast Chinese market.
Monthly dynamics of market capitalization of the market segment - General oncology therapy
HUTCHMED is a biopharmaceutical company specializing in the development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immune diseases. The dynamics of its sector, shown in the chart, reflect the risks of R&D. Against this backdrop, it is possible to assess how the company's drug portfolio and focus on the Chinese and global markets impact its prospects in the global fight against cancer.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
HUTCHMED is a biopharmaceutical company focused on developing oncology drugs. Its shares, like many biotech companies, are awaiting clinical trial data. The chart below shows how the company's performance has been out of sync with the broader market, driven by specific news rather than macroeconomic factors.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization HCM
HUTCHMED's weekly stock price reflects investor sentiment in the oncology-focused biotech sector. The stock price reacts strongly to the publication of clinical trial results, regulatory decisions, and partnership news. The chart below illustrates how short-term events in the world of science and medicine shape the company's value.
Weekly dynamics of market capitalization of the market segment - General oncology therapy
How does HUTCHMED's performance compare to the broader biotech sector? This chart compares the company's weekly stock price movements, driven by news of its oncology clinical trials, with the overall trend. This helps us understand whether the stock's movement is the result of a unique event or a reflection of overall investor sentiment in this volatile industry.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
HUTCHMED develops innovative cancer treatments, targeting both the Chinese and global markets. This chart compares its weekly performance to the broader market. It helps understand what's driving the stock: general biotech sentiment, news from China, or the release of clinical trial data.
Market capitalization of the company, segment and market as a whole
HCM - Market capitalization of the company HCM
HUTCHMED (China) Limited's market valuation is a bet on its ability to develop innovative cancer treatments. This biopharmaceutical company's market cap is closely tied to the success of its clinical trials and partnerships. The chart illustrates investors' confidence in its scientific potential in the global oncology market.
HCM - Share of the company's market capitalization HCM within the market segment - General oncology therapy
HUTCHMED (China) Limited is a biopharmaceutical company developing innovative cancer treatments. Its market capitalization in the oncology sector reflects the potential of its developments and its reach into global markets. The chart demonstrates how clinical trial success and drug approvals shape its market share and investment appeal.
Market capitalization of the market segment - General oncology therapy
The chart illustrates the total value of the oncology-focused biotech sector, an arena worth hundreds of billions of dollars. HUTCHMED, with its unique research model in China, is a vital part of this global fight against cancer. The dynamics in the chart reflect the widespread hope for new drugs.
Market capitalization of all companies included in a broad market index - GURU.Markets
The chart shows the market valuation of the bridge between Western and Chinese biotech. HUTCHMED's market capitalization reflects the value of its portfolio of cancer drugs developed in China for the global market. This line visualizes how scientific innovations from Asia are gaining a foothold in the global pharmaceutical industry.
Book value capitalization of the company, segment and market as a whole
HCM - Book value capitalization of the company HCM
The graph below visualizes the inventory of HUTCHMED (China), a biopharmaceutical company. Its line reflects the value of its research centers, manufacturing facilities, and patents for innovative cancer treatments. Growth in this indicator indicates investment in research and the expansion of production to combat cancer.
HCM - Share of the company's book capitalization HCM within the market segment - General oncology therapy
HUTCHMED's resources include modern research centers and manufacturing facilities for the development of innovative oncology drugs. The chart shows the company's control over the company's share of the advanced pharmaceutical infrastructure in its niche, demonstrating its full-cycle capabilities—from development to production.
Market segment balance sheet capitalization - General oncology therapy
HUTCHMED is a biopharmaceutical company. Unlike "light" startups, it has not only R&D centers but also its own drug manufacturing plants. This makes it more capital-intensive. The graph will show whether this hybrid model (science and manufacturing) is the norm for the entire pharmaceutical industry.
Book value of all companies included in the broad market index - GURU.Markets
HUTCHMED's balance sheet includes modern laboratories, manufacturing facilities, and a portfolio of patents for oncology drugs. The company's assets represent capital transformed into scientific and manufacturing potential to fight cancer. The chart illustrates the scale of this biopharmaceutical company in the global market.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - HCM
HUTCHMED's balance sheet reflects its cash reserves and research facilities. However, its market capitalization is built on its portfolio of oncology drugs already approved in China and its extensive pipeline of new drugs. The chart shows how investors value its ability to develop and commercialize innovative cancer treatments, not its current tangible assets.
Market to book capitalization ratio in a market segment - General oncology therapy
HUTCHMED is a biopharmaceutical company developing cancer drugs. Like many companies in this field, its primary assets are not buildings, but a pipeline of research drugs. This metric reflects the significant premium the market is pricing in the company in anticipation of successful clinical trials and the launch of new drugs.
Market to book capitalization ratio for the market as a whole
HUTCHMED is a biopharmaceutical company developing and commercializing cancer treatments. This chart shows how the market values its scientific potential and drug pipeline. The huge premium of its market capitalization to its book value reflects investors' faith in the future sales of its drugs and the success of its clinical trials, not the value of its laboratories.
Debts of the company, segment and market as a whole
HCM - Company debts HCM
HUTCHMED (China) Limited is a biopharmaceutical company focused on developing cancer drugs. The journey from lab to patient requires significant investment. Debt capital can serve as a bridge between funding rounds, allowing costly research to continue. This chart provides insight into the company's financial strategy on the path to new discoveries.
Market segment debts - General oncology therapy
HUTCHMED is a biopharmaceutical company focused on developing drugs for the treatment of cancer and immune diseases. The biotech financial model is built on long-term investments in research. This chart shows common financial metrics for the pharmaceutical industry, which can be used to assess how HUTCHMED finances its extensive pipeline of developments prior to commercialization.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio HCM
HUTCHMED is a biopharmaceutical company focused on developing and commercializing cancer treatments. Clinical trials in oncology are extremely expensive. This chart shows the company's reliance on debt financing to advance its broad pipeline of drug candidates to market.
Market segment debt to market segment book capitalization - General oncology therapy
HUTCHMED is a biopharmaceutical company focused on developing cancer drugs, which requires colossal investments in multi-year research. This chart compares its debt raised for R&D to the overall market capitalization of the oncology sector. It demonstrates the company's high stakes in the race to develop new treatments.
Debt to book value of all companies in the market
HUTCHMED, a biopharmaceutical company, incurs debt to fund expensive research. This chart compares its liabilities to the overall market capitalization. It shows how the innovative company's financial needs compare to its overall market value and where it draws the resources to fuel its breakthrough developments.
P/E of the company, segment and market as a whole
P/E - HCM
This metric for HUTCHMED, a biopharmaceutical company focused on oncology, shows its market valuation based on its current profitability. For a company that invests heavily in research, its value is determined by the future potential of its drugs. The chart reflects investors' confidence in its scientific pipeline and ability to bring drugs to market.
P/E of the market segment - General oncology therapy
This metric represents the average valuation for the biotech sector in which HUTCHMED operates. In this industry, filled with research-stage companies, the average earnings valuation is often uninformative. However, it reflects the overall level of investor optimism regarding scientific breakthroughs and serves as a benchmark for understanding the company's value.
P/E of the market as a whole
HUTCHMED is a biopharmaceutical company focused on developing innovative drugs for the treatment of cancer and immune diseases. The company aims to become a global leader in oncology. This chart, reflecting investor risk appetite, helps understand how the overall market evaluates long-term and capital-intensive biotech projects.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company HCM
HUTCHMED is a biopharmaceutical company focused on developing and commercializing drugs for the treatment of cancer and immune diseases. This chart reflects investor expectations regarding the success of its clinical trials and future drug sales. It represents the market's assessment of the company's scientific potential and its ability to bring new drugs to market.
%20P%2FE%20HCM&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-HCM&v=1772522301407 "Chart of the company's future (projected) P/E HCM")
Future (projected) P/E of the market segment - General oncology therapy
HUTCHMED (formerly Hutchison China MediTech) is an innovative biopharmaceutical company focused on the discovery, development, and commercialization of targeted and immunotherapeutic drugs for the treatment of cancer and immune diseases. This chart shows average expectations for the biotech sector, helping to evaluate HUTCHMED against the broader oncology industry outlook.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-General-oncology-therapy&v=1772522301481 "Future (projected) P/E graph of the market segment - General oncology therapy")
Future (projected) P/E of the market as a whole
HUTCHMED (China) Limited is a biopharmaceutical company focused on developing and commercializing innovative drugs for the treatment of cancer and immune diseases. Its success is driven by clinical trial results and penetration into the vast Chinese market, making it less dependent on global market cycles.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772522301545 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit HCM
HUTCHMED (China) Limited is an innovative biopharmaceutical company focused on the development and commercialization of targeted therapies and immunotherapies for cancer treatment. Its revenues are generated both from sales of approved drugs and from R&D expenditures. This chart reflects the balance between current revenue and significant investments in future breakthrough drugs.
Profit of companies in the market segment - General oncology therapy
HUTCHMED (China) Limited is a biopharmaceutical company specializing in the development of innovative drugs for the treatment of cancer and immune diseases. This chart shows the total profitability of the oncology segment. Being at the forefront of science, HUTCHMED invests heavily in R&D, which impacts current overall profitability, but its breakthroughs have the potential to drive future growth for the entire industry.
Overall market profit
HUTCHMED (China) Limited is a biopharmaceutical company focused on developing drugs for cancer and immune diseases. Its value is created in laboratories and clinics, not factories. While this chart illustrates the ups and downs of a traditional economy, HUTCHMED's success depends on scientific breakthroughs that can change patients' lives, regardless of market conditions.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company HCM
HUTCHMED is a biopharmaceutical company focused on developing and commercializing innovative drugs for the treatment of cancer and immune diseases. This chart reflects analysts' expectations for future revenue, which depend on the success of clinical trials, regulatory approvals, and sales volumes of existing drugs, primarily in China and globally.
%20profit%20of%20the%20company%20HCM&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-HCM&v=1772522301948 "Graph of future (projected) profit of the company HCM")
Future (predicted) profit of companies in the market segment - General oncology therapy
HUTCHMED (China) Limited is an innovative biopharmaceutical company focused on the development and commercialization of targeted therapies and immunotherapies for cancer treatment. This chart shows profitability forecasts for the oncology segment. It reflects the general expectations for breakthroughs in cancer treatment that could radically change the prospects of developers like HCM.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-General-oncology-therapy&v=1772522302084 "Graph of future (predicted) profits of companies in a market segment - General oncology therapy")
Future (predicted) profit of the market as a whole
HUTCHMED is a biopharmaceutical company focused on developing drugs for cancer and immune diseases. Funding for such cutting-edge research depends on the investment climate. The company's earnings forecast reflects the overall market situation. Positive momentum facilitates HUTCHMED's ability to attract the capital it needs to bring its life-saving drugs to market.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772522302184 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - HCM
HUTCHMED is a biopharmaceutical company focused on developing drugs for cancer and immune diseases. For a company bringing new drugs to market, the P/S ratio reflects how investors assess the commercial success of its portfolio. It represents the belief that current sales are just the beginning of a long journey toward conquering the oncology market.
P/S market segment - General oncology therapy
HUTCHMED (formerly Hutchison China MediTech) is a biopharmaceutical company developing innovative drugs for the treatment of cancer and immune diseases. Its valuation reflects the potential of its developments. This chart helps understand the premium investors place on its research and future revenue streams compared to other oncology companies.
P/S of the market as a whole
HUTCHMED (China) Limited is a biopharmaceutical company focused on cancer drug development. Its revenue is generated from both approved drugs and anticipated new developments. This chart shows the average revenue estimate, allowing one to assess the market premium for innovation and growth potential in the oncology sector.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company HCM
HUTCHMED is a biopharmaceutical company focused on developing innovative cancer treatments. Its value is determined by the potential of its oncology pipeline. This chart reflects investor expectations for future sales of its drugs, both approved and in development, in the vast oncology market.
%20P%2FS%20HCM&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-HCM&v=1772522302533 "The graph of the company's future (projected) P/S HCM")
Future (projected) P/S of the market segment - General oncology therapy
HUTCHMED (China) Limited is an innovative biopharmaceutical company developing and commercializing targeted therapies and immunotherapies for cancer treatment. This chart compares market expectations for its future sales with those of other oncology companies. It shows how highly investors value its scientific potential and drug pipeline.
%20P%2FS%20market%20segment%20graph%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-General-oncology-therapy&v=1772522302604 "Future (projected) P/S market segment graph - General oncology therapy")
Future (projected) P/S of the market as a whole
HUTCHMED is a biopharmaceutical company focused on developing innovative cancer treatments. Its market capitalization reflects expectations for future breakthroughs in oncology. This chart shows investors' overall revenue forecasts, and using HCM as an example, it illustrates how the biotech sector, fraught with risks and potential breakthroughs, influences long-term market optimism.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772522302671 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales HCM
HUTCHMED (formerly Chi-Med) is an innovative biopharmaceutical company focused on the development and commercialization of targeted therapies and immunotherapies for the treatment of cancer. Its revenue, as reflected in the chart, consists of sales of approved drugs and payments from collaborations with major pharmaceutical companies. Growth depends on the success of new developments and market expansion.
Sales of companies in the market segment - General oncology therapy
HUTCHMED is a biopharmaceutical company focused on developing cancer drugs. This chart illustrates the components of its commercial success. It breaks down revenue between its proprietary oncology drugs sold in China and revenue from other commercial partnerships, illustrating its hybrid business model.
Overall market sales
HUTCHMED is a biopharmaceutical company developing innovative cancer treatments. Its success is determined by clinical trial results and its ability to bring new drugs to market. The macroeconomic trends visible in this chart are secondary to scientific advancements and regulatory approvals.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company HCM
HUTCHMED is a biopharmaceutical company focused on developing cancer drugs. Its revenue forecast reflects analyst expectations for the success of clinical trials and the commercialization of new oncology drugs. This chart shows Wall Street's confidence in the scientific and commercial potential of its developments in the fight against cancer.
%20sales%20of%20the%20company%20HCM&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-HCM&v=1772522302995 "Schedule of future (projected) sales of the company HCM")
Future (projected) sales of companies in the market segment - General oncology therapy
HUTCHMED is a biopharmaceutical company focused on developing cancer treatments. This chart displays projected revenues for the entire oncology therapeutics segment. It allows us to estimate how quickly experts expect this market to grow. For HUTCHMED, this is a key metric, demonstrating the potential demand for their innovative drugs.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-General-oncology-therapy&v=1772522303019 "Schedule of future (projected) sales of companies in the market segment - General oncology therapy")
Future (projected) sales of the market as a whole
HUTCHMED is a biopharmaceutical company focused on developing drugs to treat cancer and immune diseases. Although demand for oncology drugs is inelastic, the overall economic forecasts presented here influence government healthcare budgets and the investment climate in biotech, which is important for funding expensive clinical trials.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772522303169 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality HCM
HUTCHMED is a biopharmaceutical company developing cancer treatments. This chart illustrates the financial trajectory of this oncology innovator. It shows how revenue from approved drugs compares to the extensive investments in research and clinical trials of new candidates, which drive future profitability.
Market segment marginality - General oncology therapy
HUTCHMED (China) is a biopharmaceutical company focused on the development and commercialization of cancer treatments. This chart illustrates the commercial potential of its drug portfolio. Its exceeding industry profitability indicates the successful launch of sought-after oncology drugs and a strong position in China.
Market marginality as a whole
HUTCHMED is a biopharmaceutical company focused on developing drugs for cancer and immune diseases. Its path is marked by lengthy and expensive research. This chart illustrates the average market profitability, while HUTCHMED operates under an all-or-nothing logic: a single successful drug can generate colossal profits, justifying years of investment and losses.
Employees in the company, segment and market as a whole
Number of employees in the company HCM
HUTCHMED (formerly Chi-Med) is a biopharmaceutical company focused on the development and commercialization of cancer treatments. Its team's growth reflects progress in clinical trials and, more importantly, the establishment of a commercial infrastructure and sales team to bring its own drugs to market, primarily in China.
Share of the company's employees HCM within the market segment - General oncology therapy
HUTCHMED (formerly Chi-Med) is an innovative biopharmaceutical company focused on developing drugs for cancer and immune diseases. This chart reflects its scientific potential. It shows the percentage of leading oncologists, researchers, and chemists in their field that HUTCHMED brings together to create and commercialize new therapeutics for the global market.
Number of employees in the market segment - General oncology therapy
HUTCHMED (China) Limited is a biopharmaceutical company focused on the development and commercialization of innovative cancer treatments. This chart shows employment in the oncology therapeutics sector. The growing number of scientists and clinicians reflects increased global investment in the fight against cancer, creating a favorable environment for HUTCHMED's research.
Number of employees in the market as a whole
HUTCHMED (China) Limited is a biopharmaceutical company developing innovative cancer treatments. Its growing staff of scientists and clinicians reflects not so much the state of the economy as progress in the fight against cancer and the influx of investment into the knowledge-intensive healthcare sector. This is an example of how it is creating the high-value jobs of the future.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company HCM (HCM)
HUTCHMED is a biopharmaceutical company focused on developing cancer drugs. Their value is determined by their patent portfolio and the potential of their drugs in clinical trials. This chart shows how much the market values their intellectual property. Even with a relatively small staff of scientists and researchers, the company can achieve a market capitalization in the billions.
%20of%20the%20company%20HCM%20(HCM)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-HCM-HCM&v=1772522303902 "Chart of market capitalization per employee (in thousands of dollars) of the company HCM (HCM)")
Market capitalization per employee (in thousands of dollars) in the market segment - General oncology therapy
HUTCHMED is a biopharmaceutical company that not only develops but also sells oncology drugs, primarily in China. This chart shows the industry average. It helps evaluate the company's hybrid model: how effective its market value (R&D + sales) is per employee compared to pure biotech companies.
%20by%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-General-oncology-therapy&v=1772522304149 "Market capitalization per employee (in thousands of dollars) by market segment - General oncology therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
HUTCHMED is a biopharmaceutical company focused on the development and commercialization of innovative drugs for the treatment of cancer and immune diseases. Value is created in the laboratory by scientists. This chart shows how highly investors value the team's intellectual potential, expecting their research to yield breakthrough therapeutic solutions.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772522304210 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company HCM (HCM)
HUTCHMED (formerly Hutchison China MediTech) is a biopharmaceutical company focused on oncology and immune diseases. The company has both its own R&D projects and a commercial operation in China. This chart reflects the hybrid model: how profitable sales of existing drugs cover the costs of R&D personnel searching for new blockbusters.
%20Chart%20HCM%20(HCM)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-HCM-HCM&v=1772522304222 "Company Profit Per Employee (in thousands of dollars) Chart HCM (HCM)")
Profit per employee (in thousands of dollars) in the market segment - General oncology therapy
HUTCHMED is a biotech company (China/Hong Kong) developing and commercializing cancer treatments. This chart shows the benchmark for the "Oncology" biotech sector. In this sector, the benchmark for profit per employee is either deeply negative (at the R&D stage) or astronomically high (when a blockbuster drug is approved).
%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-General-oncology-therapy&v=1772522304296 "Chart of profit per employee (in thousands of dollars) in the market segment - General oncology therapy")
Profit per employee (in thousands of dollars) for the market as a whole
HUTCHMED is a biopharmaceutical company with a strong R&D base in China, focused on cancer treatment. This indicator, which shows the average contribution of one employee to profit, asks the question: how does the oncology R&D sector, where HCM operates (and where investments are significant), compare to the overall market rate of return per employee?
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772522304362 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee HCM (HCM)
HUTCHMED is a biopharmaceutical company focused on oncology. This chart reflects its journey from research to commercialization. While drugs are in development, this metric may be low. However, successfully launching a drug leads to explosive growth in revenue per employee, demonstrating the value of the intellectual property created.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-HCM-HCM&v=1772522304508 "Sales chart per company employee HCM (HCM)")
Sales per employee in the market segment - General oncology therapy
HUTCHMED is a biopharmaceutical company focused on oncology and immunology, with a strong presence in China. This chart shows the average revenue per employee in this segment. For a company that combines R&D and commercialization, it demonstrates how productive its scientific and commercial staff is compared to its global pharmaceutical competitors.
Sales per employee for the market as a whole
HUTCHMED (China) Limited is a biopharmaceutical company focused on oncology. The company operates at the intersection of R&D and commercialization. This metric reflects how successfully the company transitions from research (high personnel costs) to sales of approved drugs. A rising graph directly indicates the successful monetization of their scientific potential.
Short shares by company, segment and market as a whole
Shares shorted by company HCM (HCM)
HUTCHMED (formerly Chi-Med) is a Hong Kong-based biopharmaceutical company focused on developing oncology drugs for the Chinese and global markets. This chart reflects concerns about their pipeline. Bears may bet on clinical trial failure, fierce competition in the oncology market, or geopolitical risks associated with Chinese stocks.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-HCM-HCM&v=1772522304988 "Short Shares Chart for the Company HCM (HCM)")
Shares shorted by market segment - General oncology therapy
HUTCHMED (HCM) is a biopharmaceutical company focused on cancer drug development with a strong presence in China. This chart highlights the pessimism in the oncology sector. The increase in short positions across the sector may indicate that investors are concerned about pricing pressure from the Chinese government or stricter FDA standards for foreign drugs, which could impact the entire group.
Shares shorted by the overall market
HUTCHMED (HCM) is a biopharmaceutical company focused on developing cancer drugs. It's a sector dependent on clinical trial success. However, this chart reflects overall market pessimism. When investors are fearful (as the index rises), they tend to avoid "risky" biotechs, especially those that haven't yet achieved stable profitability, like HCM, and sell them off regardless of the science.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator HCM (HCM)
HUTCHMED is a Chinese biotech company focused on oncology. The business carries dual risks (biotech and China). This chart for HCM above 70 may reflect R&D success or optimism about China. Below 30 is associated with setbacks, regulatory pressure, or a recession in China.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-HCM-HCM&v=1772522305350 "RSI 14 indicator chart for the company's stock HCM (HCM)")
RSI 14 Market Segment - General oncology therapy
HUTCHMED (formerly Hutchison China MediTech) is a biotech company specializing in the development and commercialization of innovative drugs for the treatment of cancer and immune diseases. This chart shows the overall momentum in the oncology biotech sector. It helps determine whether the entire segment is overheated by expectations of new treatment breakthroughs.
RSI 14 for the overall market
HUTCHMED, a Chinese oncology biotech, sees a dual risk in this chart. During periods of euphoria, investors are willing to fund both risky research and investments in emerging markets. During moments of panic, capital flees both biotech and Chinese assets, creating a perfect storm for the company.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast HCM (HCM)
HUTCHMED (China) Limited is a biopharmaceutical company focused on developing innovative cancer treatments. This chart shows the average analyst consensus. Their target prices are based on complex models that assess the likelihood of clinical trial success, the potential market reach of new oncology drugs, and partnerships.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-HCM-HCM&v=1772522305705 "A chart showing analyst consensus forecasts for the expected stock price. HCM (HCM)")
The difference between the consensus estimate and the actual stock price HCM (HCM)
HUTCHMED is a Chinese biopharmaceutical company specializing in the discovery and development of innovative targeted cancer therapies. Their goal is to bring their drugs to the global market. This chart shows analyst confidence in their R&D pipeline and commercial potential. It reflects the gap between the consensus estimate and the current price.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-HCM-HCM&v=1772522305711 "A chart showing the difference between the consensus forecast and the actual stock price. HCM (HCM)")
Analyst consensus forecast for stock prices by market segment - General oncology therapy
HUTCHMED is one of China's leading innovative biopharmaceutical companies, focused on developing new cancer treatments. This chart shows analysts' overall expectations for the entire oncology sector. It reflects whether experts believe breakthroughs in cancer treatments are possible or whether they consider the sector overheated.
Analysts' consensus forecast for the overall market share price
HUTCHMED (HCM) is a biopharmaceutical company based in China. They specialize in developing and commercializing innovative drugs for the treatment of cancer and immune diseases. This chart shows the overall risk appetite in the market. It reflects the willingness of investors to fund global biotech, including the Chinese sector.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index HCM
HUTCHMED is a biotech company based in China focused on developing and commercializing innovative cancer treatments. This chart is a summary of their R&D pipeline. It likely reflects their current revenue from approved drugs in China and market expectations from their global clinical trials.
AKIMA Market Segment Index - General oncology therapy
HUTCHMED is a Chinese biotech company, a pioneer in the development of innovative targeted drugs for cancer treatment. The company is successfully commercializing its drugs in China. This summary metric evaluates R&D. The graph shows the average value for the segment. This benchmark: how does HUTCHMED's Chinese R&D platform differentiate it from the average pharmaceutical company?
The AKIM Index for the overall market
HUTCHMED is a Chinese biotech company focused on oncology (cancer). The company markets drugs both in China and globally. This chart, showing the average (global/US) market share, serves as a benchmark. It helps assess how this Chinese research story compares to overall macroeconomic trends that influence risk appetite.
